Specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ: SUPN) announced better-than-expected revenue in Q3 2026, with sales up 18.1% year on year to $226.8 million. The company’s full-year revenue guidance of $887.5 million at the midpoint came in 1.5% above analysts’ estimates. Its non-GAAP profit of $0.88 per share was 79.2% above analysts’ consensus estimates.

Is now the time to buy SUPN? Find out in our full research report (it’s free for active Edge members).

StockStory’s take

Supernus Pharmaceuticals’ third quarter was marked by strong revenue growth and operational improvements, yet the market responded negatively. Management cited momentum across its core neurology and psychiatry products, particularly Qelbree, ZURZUVAE, ONAPGO, and GOCOVRI, as the primary drivers. CEO Jack Khattar highlighted prescription volume growth above broader market trends, with Qelbree prescriptions rising 18% year-over-year and ONAPGO rebounding after supply constraints. He acknowledged that “all the supply issues are behind us right now,” allowing for smoother fulfillment and ongoing process optimization.

Looking forward, Supernus’ updated guidance and business priorities are shaped by continued investment in its core growth products and the integration of Indivior Pharmaceuticals. Management emphasized that the near-term focus will be on combining operations, capturing $125 million in annual cost synergies, and leveraging an expanded commercial portfolio. Khattar stated, "We are entering an exciting new chapter that builds on a strong foundation," noting that future growth will depend on both pipeline advancement and maximizing existing product opportunities, especially through targeted physician and patient education initiatives.

Key insights from management’s remarks

Management attributed the quarter’s performance to portfolio-wide prescription and demand growth, operational normalization in ONAPGO, and initial integration planning with Indivior.

• Qelbree prescription momentum: Qelbree outpaced the ADHD market, with 18% growth in total prescriptions, driven by both adult and pediatric segments. Management noted strong adult segment growth during the typically pediatric-focused back-to-school season, with 25% growth in adult prescriptions versus 16% in pediatric.

• ONAPGO supply recovery: Following a backlog in earlier quarters, ONAPGO returned to normal operations, with net sales up 27% sequentially and prescription processing delays resolved. Management has optimized form submission to shipment timing, enhancing conversion rates and supporting renewed growth.

• ZURZUVAE collaboration progress: ZURZUVAE, marketed in partnership with Biogen, saw 43% year-over-year prescription growth and a 53% increase in U.S. sales as reported by Biogen. Supernus credited a direct-to-consumer campaign and high repeat prescriber rates (87% of prescriptions) for sustained demand.

• GOCOVRI steady expansion: GOCOVRI achieved record net sales and prescription levels, growing 4% year-over-year. Management framed this as evidence of sustained demand in movement disorder therapies, despite a competitive market.

• Merger integration underway: With shareholder approval, Supernus and Indivior are preparing to combine operations. Management is confident in realizing $125 million in annual cost synergies and expects to focus on pipeline advancement and maximizing the combined portfolio’s reach.

Drivers of future performance

Supernus’ outlook is defined by portfolio scaling, integration execution, and continued investment in product education and market expansion.

• Integration with Indivior: Management’s primary near-term focus is on integrating Indivior and Supernus, aiming to achieve $125 million in annual cost synergies. This includes streamlining operations and leveraging combined expertise across psychiatry, neurology, and addiction franchises.

• Product growth initiatives: The company plans to further invest in direct-to-consumer and provider education campaigns for key brands such as ZURZUVAE and Qelbree, aiming to expand awareness and improve market penetration. Management highlighted untapped potential, particularly in adult ADHD and postpartum depression segments.

• Pipeline and M&A opportunities: While near-term attention is on integration, management signaled ongoing interest in mergers and acquisitions as well as advancing late-stage pipeline candidates like SPN-817 and SPN-443, though recruitment and trial progress in epilepsy and depression remain gradual and subject to industry-wide timelines.

Catalysts in upcoming quarters

In the coming quarters, our team will monitor (1) the success of Supernus’ integration with Indivior in achieving cost synergies and operational alignment, (2) the continued momentum of Qelbree and ZURZUVAE in both prescription and market share growth, and (3) progress in pipeline development, especially the advancement of SPN-817 and SPN-443. Execution of new commercial initiatives and further clarity on capital allocation strategies will also be important indicators of future performance.

Supernus Pharmaceuticals currently trades at $42.45, up from $41.84 just before the earnings. Is there an opportunity in the stock? The answer lies in our full research report (it’s free).

Now could be the perfect time to invest in these stocks

ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren’t just high-quality businesses. Something is happening with them right now. Elite fundamentals meet near-term momentum — both boxes checked at the same time.

Find out which stocks our AI platform is flagging this week. See this week’s Strong Momentum stocks — FREE. Get Our Strong Momentum Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,552% between June 2020 and June 2025). Find your next big winner with StockStory today.